Hematology Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for hematology dealmaking

Hematology partnering spans both malignant and non-malignant disorders, with deal structures reflecting the increasing use of targeted therapies, biologics, and advanced treatment modalities across the space.

This report provides a comprehensive and structured analysis of 226 hematology collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how hematology deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by stage, asset type, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a technically advanced and evolving therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within hematology partnerships, particularly in areas involving complex development pathways and high-value therapies.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark live transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data
What's included
226 hematology collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy, and technology)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for hematology dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how hematology partnerships are structured, negotiated, and valued.

Product Code: CP2207

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

2.1. Introduction
2.2. Hematology partnering over the years
2.3. Hematology partnering by deal type
2.4. Hematology partnering by industry sector
2.5. Hematology partnering by stage of development
2.6. Hematology partnering by technology type
2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

3.1. Introduction
3.2. Disclosed financials terms for hematology partnering
3.3. Hematology partnering headline values
3.4. Hematology deal upfront payments
3.5. Hematology deal milestone payments
3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

4.1. Introduction
4.2. Most active in hematology partnering
4.3. List of most active dealmakers in hematology
4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

5.1. Introduction
5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by hematology therapeutic target
Deal directory
Deal directory - Hematology deals by company A-Z
Deal directory - Hematology deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Hematology partnering since 2016
Figure 2: Hematology partnering by deal type since 2016
Figure 3: Hematology partnering by industry sector since 2016
Figure 4: Hematology partnering by stage of development since 2016
Figure 5: Hematology partnering by technology type since 2016
Figure 6: Hematology partnering by indication since 2016
Figure 7: Hematology deals with a headline value
Figure 8: Hematology deals with upfront payment values
Figure 9: Hematology deals with milestone payment
Figure 10: Hematology deals with royalty rates
Figure 11: Active hematology dealmaking activity since 2016
Figure 12: Top hematology deals by value since 2016